Publications by authors named "C L Haass-Koffler"
Background: Intranasal administration of the neuropeptide oxytocin has been explored as a potential therapeutic agent for substance use disorder including opioid use disorder (OUD).
Methods: This phase 1, crossover, randomized, double-blind, placebo-controlled trial tested the safety, tolerability, and efficacy of intranasal oxytocin (80 IU) twice a day for 7 days in participants ( = 20) with OUD who were taking an opioid agonist therapy. In the laboratory, participants underwent opioid cue exposure paired with noradrenergic activation produced by yohimbine (32.
Article Synopsis
- - This study provides early evidence that pannexin 1 channels could be a new target for creating treatments for alcohol use disorder (AUD), highlighting probenecid’s potential due to its long safety history and ability to reduce excessive alcohol intake in animal models.
- - A randomized trial involving 35 participants explored the effects of a 2g dose of probenecid taken with alcohol, measuring various outcomes like alcohol craving and cognitive function, finding no significant impact on alcohol absorption or overall cognitive ability.
- - Results indicated that probenecid notably reduced alcohol cravings during the early phase of intoxication, supporting its potential as a treatment for AUD and emphasizing the need for further research on pannexin 1 channels for new drug development
Recent years have seen a resurgence in randomized, placebo controlled trials (RCTs) utilizing non-classical psychedelics (e.g. 3,4-methyl enedioxy methamphetamine [MDMA]), and classical psychedelics (e.
View Article and Find Full Text PDFThis systematic review investigates the bidirectional relationship between alcohol consumption and disrupted circadian rhythms. The goal of this study was to identify (i) the types of circadian rhythm disruptors (i.e.
View Article and Find Full Text PDF